Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126616 | 0.72 | MAPT (0.33) | MEN1KMT2A | |
| SCHEMBL6142539 | 0.69 | PDPK1 (0.30) | MEN1KMT2A | |
| SCHEMBL8927070 | 0.68 | L3MBTL1 (0.38) | MEN1KMT2A | |
| Bromide SCHEMBL6142159 | 0.68 | — | — | |
| SCHEMBL6142564 | 0.65 | PDPK1 (0.37) | XDHCYP3A4MEN1CSNK2A2RAB9A | |
| SCHEMBL8926989 | 0.65 | ADRA2A (0.52) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10111202 | 0.64 | PDPK1 (0.41) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL25647646 | 0.63 | ABL1 (0.44) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL10126613 | 0.62 | HTR1A (0.36) | — | |
| SCHEMBL6581839 | 0.61 | PDPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | CDH1, EPCAM, CD4 | XDH 3812/4885CYP1A2 2849/4885CYP3A4 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.